A comprehensive technology platform utilizing chemiluminescence immunoassay methodology for in vitro diagnostic testing. The platform enables sensitive and specific detection of various clinical markers including reproductive, autoimmune, infectious disease, and metabolic parameters.
Manufactured by
Shenzhen, China
Founded in 2008, Shenzhen YHLO Biotech Co., Ltd. (YHLO) is a publicly listed company on the Science and Technology Innovation Board (stock code: 688575). Based in Shenzhen, YHLO excels in the research, development, production, sales, and service of in vitro diagnostic (IVD) products. Recognized as a national high-tech enterprise with extensive independent intellectual property rights, YHLO has earned numerous accolades, including being named a National Intellectual Property Demonstration Enterprise and one of Shenzhen's Top 70 Innovative Enterprises. YHLO utilizes six advanced IVD technology platforms, including chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. With a portfolio of over 300 products addressing areas such as autoimmunity, reproductive health, infection, liver disease, and respiratory diseases, YHLO's products are widely implemented across hospitals, community clinics, and third-party testing centers, with a coverage rate exceeding 70% in China's top-tier hospitals. While firmly rooted in the domestic market, YHLO actively expands its international presence, with products exported to nearly 115 countries and regions, gaining recognition and trust from global customers. YHLO has made substantial investments in research and development, establishing research centers in Tokyo, Japan; Wuhan, China; and Changsha, China, as well as setting up a production base in Xiangtan, China. As of August 30, 2024, the company has filed for 681 patents, including 58 PCT patents, 367 invention patents, 167 utility model patents, and 22 design patents. YHLO prioritizes the integration of industry, academia, and research, establishing collaborative laboratories with prestigious institutions such as Peking University, the Institute of Biophysics of the Chinese Academy of Sciences, the Chinese University of Hong Kong (Shenzhen), the Southern University of Science and Technology, the Third People's Hospital of Shenzhen, Huazhong University of Science and Technology, and the National Innovation Center for High-Performance Medical Devices. YHLO adheres to the mission of Focus on healthcare, better life with technology, consistently striving for excellence and delivering outstanding products and services for human health, with the goal of being a leading enterprise in the life sciences and a global leader in in vitro diagnostics.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
Jiangsu Sunlant Bioengineering Co., Ltd.
China · 1 relevant product
Xenta Biomedical Science Co.,Ltd
China · 2 relevant products
S&T BioMed CO., LTD.
Taiwan · 1 relevant product
Sekbio Co., Ltd
China · 1 relevant product
ReLIA Bioengineering(Jiangsu), Inc
China · 1 relevant product
Sichuan Orienter Biotechnology Co., Ltd.
China · 1 relevant product
Render Biotech Co., Ltd.
China · 2 relevant products
DRG Instruments GmbH
Germany · 1 relevant product
Guangzhou Yichuan Biological Technology Co.,Ltd.
China · 1 relevant product
17 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 33 closest product alternatives
Guangzhou Wondfo Biotech Co., Ltd. · China
Chemiluminescence diagnostic platform for quantitative and qualitative analysis of biomarkers in patient samples. Delivers sensitive detection capabilities for clinical laboratory and point-of-care applications.
Jiangsu Sunlant Bioengineering Co., Ltd. · China
A microarray-based chemiluminescence immunoassay platform using hard-substrate glass slides as carriers with covalently bound monoclonal antibodies. The platform features integrated positive and negative quality control points, multi-parameter detection with up to 56 array points, and a sandwich immunoassay methodology. It combines high-sensitivity chemiluminescence detection with high-throughput biochip technology using an integrated photoelectric sensor to read all signal points simultaneously.
Xenta Biomedical Science Co.,Ltd · China
A diagnostic platform featuring high sensitivity and wide detection menu that comprehensively covers critical care, cardiovascular and cerebrovascular diseases, and other key clinical areas. The platform is widely applied in clinical departments such as laboratory medicine, emergency medicine, and ICU, while also suitable for diverse scenarios including primary healthcare facilities, health examination centers, and reproductive centers.
Xenta Biomedical Science Co.,Ltd · China
A proprietary dry-phase photoactivated chemiluminescence technology platform for point-of-care testing. Covers cardiovascular, inflammatory, tumor marker, hormone, and infectious disease diagnostics.
S&T BioMed CO., LTD. · Taiwan
Automated immunoassay system utilizing electrochemical detection methods for biomarker quantification. Suitable for high-throughput clinical laboratory applications.
Sekbio Co., Ltd · China
CLIA platform providing results in 30-60 minutes with sandwich and competitive immunoassay formats. Features very high sensitivity at pg/mL range with wide dynamic range of 3-5 logs and compatibility with major analyzers.
ReLIA Bioengineering(Jiangsu), Inc · China
A compact, intelligent chemiluminescence detection platform designed for accurate diagnostic testing. The system features 20+10 independent detection channels that can perform parallel testing, delivering results within 15 minutes with low maintenance costs and extended reagent shelf life. It utilizes acridinium ester chemiluminescence technology with direct marker participation in the luminescence reaction, achieving high sensitivity and stability with coefficient of variation (CV) ≤3%, combining the precision of chemiluminescence with the convenience of point-of-care testing.
Sichuan Orienter Biotechnology Co., Ltd. · China
A chemiluminescence-based immunoassay system for laboratory diagnostics. It utilizes chemiluminescence technology to detect and measure specific analytes in patient samples for various clinical applications.
Render Biotech Co., Ltd. · China
An automated analyzer for point-of-care testing (POCT) that performs chemiluminescence immunoassays. The device is designed for immunological testing applications and is part of the company's in vitro diagnostic automation product portfolio.
DRG Instruments GmbH · Germany
Chemiluminescent-based immunoassays for routine and research diagnostic applications. Offers improved sensitivity and specificity compared to traditional ELISA methods.
Guangzhou Yichuan Biological Technology Co.,Ltd. · China
Chemiluminescence-based diagnostic reagents for immunoassay testing in clinical laboratories. The reagents are designed for high-throughput analysis on automated immunoassay analyzer systems.
SJK Global LLC · United States
Light-based immunoassay technology for both high-throughput laboratory analyzers and point-of-care platforms. CLIA offers rapid results with high sensitivity for clinical diagnostics.
21 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products